Long-Term Liver-Targeted AAV8 Gene Therapy for Mucopolysaccharidosis IVA
Current Issues in Molecular Biology · 29.10.2025 · 47 (11) · 900
DOI: 10.3390/cimb47110900 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Issues in Molecular Biology, online erschienen am 29.10.2025. Verfasst von Shaukat A Khan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Research, Nemours Children's Health, Wilmington, DE 19803, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS, NIH HHS, Austrian MPS Society.
Abstract (Originalsprache)
Mucopolysaccharidosis IVA (MPS IVA) is a lysosomal storage disease with an autosomal recessive trait caused by the deficiency of N-acetylgalactosamine-6-sulfate sulfatase (GALNS) enzyme, which leads to the accumulation of chondroitin-6-sulfate and keratan sulfate, primarily in cartilage and its extracellular matrix, resulting in a direct impact on cartilage and bone development, as well as subsequent systemic skeletal dysplasia. ERT and HSCT are current treatment options, but they have a limited effect on bone lesions. In this article, we investigated liver-specific AAV8 vectors with a thyroxine-binding globulin promoter in the MPS IVA murine model to evaluate the long-term (24 weeks in males and 48 weeks in females) effects of gene therapy on biochemical markers and bone pathology. Both treated groups showed GALNS enzyme activity at supraphysiological levels in plasma and in various tissues, including the liver, heart, spleen, and bone. Keratan sulfate in both groups was normalized in plasma, liver, and bone (male mice). Pathological analyses revealed a decrease in vacuolated cells in the heart muscle and valves and improvement in bone pathology in treated male mice. However, the therapeutic impact was less pronounced in treated female mice. Overall, male mice indicated a substantial improvement in biochemical parameters and pathology compared to female mice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biomedical Research, Nemours Children's Health, Wilmington, DE 19803, USA.
- Institute for the Study of Inborn Errors of Metabolism, Faculty of Science, Pontificia Universidad Javeriana, Bogotá 110231, Colombia.
- Department of Biological Sciences, University of Delaware, Newark, DE 19716, USA.
- Department of Pediatrics, Hospital Clínico Universitario de Santiago de Compostela, Health Research Institute of Santiago de Compostela (IDIS), CIBERER, MetabERN, 15706 Santiago de Compostela, Spain.
- Department of Pediatrics, Shimane University, Izumo 693-8501, Japan.
- Department of Pediatrics, Graduate School of Medicine, Gifu University, Gifu 501-1193, Japan.
ORCID-Profile: Eliana Benincore-Florez, Jose Victor Álvarez, Shunji Tomatsu
Förderung
- NICHD NIH HHS
- NIH HHS
- Austrian MPS Society
- A Cure for Robert, Inc.
- The Carol Ann Foundation
- Angelo R. Cali & Mary V. Cali Family Foundation, Inc.
- The Vain and Harry Fish Foundation, Inc.
- The Bennett Foundation
Zitieren
APA
Khan, S. A., Benincore-Florez, E., Nidhi, F., Álvarez, J. V., Holder, D. A., & Tomatsu, S. (2025). Long-Term Liver-Targeted AAV8 Gene Therapy for Mucopolysaccharidosis IVA. Current Issues in Molecular Biology, 47(11), 900. https://doi.org/10.3390/cimb47110900
Vancouver
Khan SA, Benincore-Florez E, Nidhi F, Álvarez JV, Holder DA, Tomatsu S. Long-Term Liver-Targeted AAV8 Gene Therapy for Mucopolysaccharidosis IVA. Current Issues in Molecular Biology. 2025;47(11):900. doi:10.3390/cimb47110900
BibTeX
@article{Khan2025,
author = {Khan, Shaukat A and Benincore-Florez, Eliana and Nidhi, Fnu and Álvarez, Jose Victor and Holder, Dione A and Tomatsu, Shunji},
title = {Long-Term Liver-Targeted AAV8 Gene Therapy for Mucopolysaccharidosis IVA},
journal = {Current Issues in Molecular Biology},
year = {2025},
volume = {47},
number = {11},
pages = {900},
doi = {10.3390/cimb47110900}
}
EUVIMED